A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease

Trial Profile

A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Sponsors Kala Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to a Kala Pharmaceuticals media release, assuming positive results from these trials, the Company anticipates submitting an NDA in the first half of 2018.
    • 25 Oct 2017 According to a Kala Pharmaceuticals media relese, the company expects to report topline data by the end of 2017.
    • 12 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top